董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Allen Barbieri | 男 | Director, Executive Vice-Chairperson of the Board and Corporate Secretary | 68 | 16.54万美元 | 11.73 | 2026-12-11 |
| Zackary Irani | 男 | Chief Executive Officer and Director | 60 | 28.55万美元 | 33.63 | 2026-12-11 |
| Gary M. Huff | 男 | Independent Director | 59 | 8.54万美元 | 5.13 | 2026-12-11 |
| Eric Bing Chin | 男 | Independent Director | 46 | 13.49万美元 | 3.88 | 2026-12-11 |
| Gary M. Huff | 男 | Independent Director | 60 | 未披露 | 未持股 | 2026-12-11 |
| Gregory Evan Feinberg | 男 | Independent Director | 42 | 未披露 | 未持股 | 2026-12-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Allen Barbieri | 男 | Director, Executive Vice-Chairperson of the Board and Corporate Secretary | 68 | 16.54万美元 | 11.73 | 2026-12-11 |
| Zackary Irani | 男 | Chief Executive Officer and Director | 60 | 28.55万美元 | 33.63 | 2026-12-11 |
| Xiaoxuan Qu | 女 | Vice President of Finance,Principal Accounting Officer and Principal Financial Officer | 33 | 未披露 | 0.27 | 2026-12-11 |
董事简历
中英对照 | 中文 | 英文- Allen Barbieri
-
Allen Barbieri，2015年6月任职董事会以来，他一直担任Biomerica, Inc.董事会的成员。他目前担任Biosynthetic Technologies, LLC的董事长兼首席执行官（2009年12月以来）。此前，他曾任职Lancer Orthodontics, Inc.的董事会，并担任Lancer Orthodontics, Inc.的首席执行官（2004年4月至2008年6月）。1999年至2004年4月，他曾处于半退休状态，担任几个私人公司的董事会的董事。他一直担任Biomerica, Inc.的董事（1999年以来）。1998年至1999年，他曾担任BUY.COM（一个大型网络零售商，拥有超过2亿美元资金的风险投资）的总裁兼首席财务官。1994年至1998年，他曾担任Pacific National Bank（商业银行于1998年出售给US Bank）的总裁兼首席执行官。任职Pacific National Bank期间，他曾担任Alta Residential Mortgage Trust（按揭房地产投资信托基金，其最大股东和创始人是Lehman Brothers）的首席执行官。此前，他曾担任Capital Bancorp（商业银行控股公司）的总裁、First Federal Bank的首席财务官，以及Merrill Lynch Capital Markets（位于纽约）投资银行副合伙人。他持有Brigham Young University的工商管理学士学位，以及麻省理工学院的斯隆管理学院（the Massachusetts Institute of Technology, Sloan School of Management）的工商管理硕士学位。
Allen Barbieri has served as an Executive Vice Chairperson of the Board and Corporate Secretary of the Company since August 2020. Since January 2022, Mr. Barbieri has also concurrently served as the Chief Executive Officer of Küleon LLC, a small private biotech company engaged in development of therapeutic drugs targeting neurologic disorders. From October 1999 through August 2020, Mr. Allen Barbieri also served as an outside independent director of the Company. From March 2015 to April 2022, Mr. Allen Barbieri served as a member of the board of directors of CareTrust REIT, Inc. (NYSE:CTRE), a large publicly traded real estate investment trust, where he served as Chairman of the Corporate Governance and Nominating Committee and as a member of the Audit and Compensation Committees. From January 2010 to March 2018, Mr. Allen Barbieri served as the Chief Executive Officer of Biosynthetic Technologies, a privately held, renewable specialty chemicals company, with BP and Monsanto as primary owners. Prior to that, from April 2004 to September 2009, Mr. Barbieri served as the Chief Executive Officer of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico. From 1998 to 1999, he served as President and Chief Financial Officer of BUY.COM, a major internet retailer, and from 1994 to 1999 Mr. Barbieri was President and Chief Executive Officer of Pacific National Bank. Mr. Allen Barbieri holds an MBA from Massachusetts Institute of Technology (MIT). - Allen Barbieri，2015年6月任职董事会以来，他一直担任Biomerica, Inc.董事会的成员。他目前担任Biosynthetic Technologies, LLC的董事长兼首席执行官（2009年12月以来）。此前，他曾任职Lancer Orthodontics, Inc.的董事会，并担任Lancer Orthodontics, Inc.的首席执行官（2004年4月至2008年6月）。1999年至2004年4月，他曾处于半退休状态，担任几个私人公司的董事会的董事。他一直担任Biomerica, Inc.的董事（1999年以来）。1998年至1999年，他曾担任BUY.COM（一个大型网络零售商，拥有超过2亿美元资金的风险投资）的总裁兼首席财务官。1994年至1998年，他曾担任Pacific National Bank（商业银行于1998年出售给US Bank）的总裁兼首席执行官。任职Pacific National Bank期间，他曾担任Alta Residential Mortgage Trust（按揭房地产投资信托基金，其最大股东和创始人是Lehman Brothers）的首席执行官。此前，他曾担任Capital Bancorp（商业银行控股公司）的总裁、First Federal Bank的首席财务官，以及Merrill Lynch Capital Markets（位于纽约）投资银行副合伙人。他持有Brigham Young University的工商管理学士学位，以及麻省理工学院的斯隆管理学院（the Massachusetts Institute of Technology, Sloan School of Management）的工商管理硕士学位。
- Allen Barbieri has served as an Executive Vice Chairperson of the Board and Corporate Secretary of the Company since August 2020. Since January 2022, Mr. Barbieri has also concurrently served as the Chief Executive Officer of Küleon LLC, a small private biotech company engaged in development of therapeutic drugs targeting neurologic disorders. From October 1999 through August 2020, Mr. Allen Barbieri also served as an outside independent director of the Company. From March 2015 to April 2022, Mr. Allen Barbieri served as a member of the board of directors of CareTrust REIT, Inc. (NYSE:CTRE), a large publicly traded real estate investment trust, where he served as Chairman of the Corporate Governance and Nominating Committee and as a member of the Audit and Compensation Committees. From January 2010 to March 2018, Mr. Allen Barbieri served as the Chief Executive Officer of Biosynthetic Technologies, a privately held, renewable specialty chemicals company, with BP and Monsanto as primary owners. Prior to that, from April 2004 to September 2009, Mr. Barbieri served as the Chief Executive Officer of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico. From 1998 to 1999, he served as President and Chief Financial Officer of BUY.COM, a major internet retailer, and from 1994 to 1999 Mr. Barbieri was President and Chief Executive Officer of Pacific National Bank. Mr. Allen Barbieri holds an MBA from Massachusetts Institute of Technology (MIT).
- Zackary Irani
-
Zackary Irani，他担任公司的董事。1997年4月29日以来，他担任公司的董事长和首席执行官。此前，他担任公司的业务发展副总裁。1986年以来，他一直担任公司的职务。在2008年和2009年的财政期间，他也担任Lancer Orthodontics, Inc.的董事长。从1997年4月到2004年4月，他担任Lancer的首席执行官。
Zackary Irani has served as a director and Chief Executive Officer of the Company since April 1997. Mr. Irani served as Chairperson of the Board from April 1997 until June 2024. Prior to that time, Mr. Zackary Irani served as the Company's Vice President of Business Development. He has been an employee of the Company since 1986. During the fiscal years 2008 and 2009, Mr. Irani also served as Chairperson of the Board of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico, and served as Lancer's Chief Executive Officer from April 1997 until April 2004. Mr. Irani holds a B.S. degree and an MBA degree from the Paul Merage School of Business at the University of California, Irvine. - Zackary Irani，他担任公司的董事。1997年4月29日以来，他担任公司的董事长和首席执行官。此前，他担任公司的业务发展副总裁。1986年以来，他一直担任公司的职务。在2008年和2009年的财政期间，他也担任Lancer Orthodontics, Inc.的董事长。从1997年4月到2004年4月，他担任Lancer的首席执行官。
- Zackary Irani has served as a director and Chief Executive Officer of the Company since April 1997. Mr. Irani served as Chairperson of the Board from April 1997 until June 2024. Prior to that time, Mr. Zackary Irani served as the Company's Vice President of Business Development. He has been an employee of the Company since 1986. During the fiscal years 2008 and 2009, Mr. Irani also served as Chairperson of the Board of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico, and served as Lancer's Chief Executive Officer from April 1997 until April 2004. Mr. Irani holds a B.S. degree and an MBA degree from the Paul Merage School of Business at the University of California, Irvine.
- Gary M. Huff
-
Gary M. Huff自2017年4月起担任LabCorp Diagnostics的首席执行官。在担任首席执行官之前，Huff先生曾担任LabCorp Diagnostics卫生系统和战略联盟部门的高级副总裁。在加入LabCorp之前，他是Baylor Miraca Genetics Laboratories BMGL的总裁兼首席执行官，这是一家由Baylor College of Medicine和日本Miraca Holdings组成的价值6800万美元的精准医学遗传学和基因组学公司。在加入BMGL之前，Huff曾担任Solstas Lab Partners的执行副总裁和COO，这是一家价值4亿美元、提供全方位服务的临床实验室，由总部在纽约的私募股权投资公司Welsh，Carson，Anderson and Stowe所有。在领导Solstas之前，他是LabCorp的高级主管。在任职期间，他担任过多个领导职务，包括：North Atlantic事业部高级副总裁、国家毒理学副总裁、销售和营销业务部副总裁，以及医院和战略联盟业务发展部执行总监。Huff先生的职业生涯始于罗氏生物医学实验室的实验室行业。
Gary M. Huff has served as the CEO of LabCorp Diagnostics since April 2017. Prior to becoming CEO, Mr. Huff served as the senior vice president of Health Systems and Strategic Alliances for LabCorp Diagnostics. Before joining LabCorp, he was the president and CEO of Baylor Miraca Genetics Laboratories BMGL, a $68M precision medicine Genetics and Genomics Company formed between Baylor College of Medicine and Miraca Holdings, Japan. Before joining BMGL, Mr. Huff served as the executive vice president and COO of Solstas Lab Partners, a $400M full-service clinical laboratory owned by the New York-based private equity firm of Welsh, Carson, Anderson, and Stowe. Before leading Solstas, he was a senior executive for LabCorp. During his tenure, he held various leadership positions to include: North Atlantic Division senior vice president, National Toxicology vice president, associate vice president of Sales and Marketing Operations, and executive director of Business Development for hospitals and strategic alliances. Mr. Huff started his career in the laboratory industry with Roche Biomedical Laboratories. - Gary M. Huff自2017年4月起担任LabCorp Diagnostics的首席执行官。在担任首席执行官之前，Huff先生曾担任LabCorp Diagnostics卫生系统和战略联盟部门的高级副总裁。在加入LabCorp之前，他是Baylor Miraca Genetics Laboratories BMGL的总裁兼首席执行官，这是一家由Baylor College of Medicine和日本Miraca Holdings组成的价值6800万美元的精准医学遗传学和基因组学公司。在加入BMGL之前，Huff曾担任Solstas Lab Partners的执行副总裁和COO，这是一家价值4亿美元、提供全方位服务的临床实验室，由总部在纽约的私募股权投资公司Welsh，Carson，Anderson and Stowe所有。在领导Solstas之前，他是LabCorp的高级主管。在任职期间，他担任过多个领导职务，包括：North Atlantic事业部高级副总裁、国家毒理学副总裁、销售和营销业务部副总裁，以及医院和战略联盟业务发展部执行总监。Huff先生的职业生涯始于罗氏生物医学实验室的实验室行业。
- Gary M. Huff has served as the CEO of LabCorp Diagnostics since April 2017. Prior to becoming CEO, Mr. Huff served as the senior vice president of Health Systems and Strategic Alliances for LabCorp Diagnostics. Before joining LabCorp, he was the president and CEO of Baylor Miraca Genetics Laboratories BMGL, a $68M precision medicine Genetics and Genomics Company formed between Baylor College of Medicine and Miraca Holdings, Japan. Before joining BMGL, Mr. Huff served as the executive vice president and COO of Solstas Lab Partners, a $400M full-service clinical laboratory owned by the New York-based private equity firm of Welsh, Carson, Anderson, and Stowe. Before leading Solstas, he was a senior executive for LabCorp. During his tenure, he held various leadership positions to include: North Atlantic Division senior vice president, National Toxicology vice president, associate vice president of Sales and Marketing Operations, and executive director of Business Development for hospitals and strategic alliances. Mr. Huff started his career in the laboratory industry with Roche Biomedical Laboratories.
- Eric Bing Chin
-
Eric Bing Chin自2025年6月起担任公司董事。Chin先生自2022年起担任XCelerant的首席战略顾问和首席财务官。Chin先生自2025年起担任PandoBlox的董事会顾问和Owl Therapy的顾问委员会成员。从2023年至2025年，Chin先生曾担任Rhode Island Primary Care Physicians Corporation的董事会成员、财务主管和秘书，并担任Akido的首席财务官。2018年至2022年，Chin先生在Astrana Health担任首席财务官，该公司是一家上市公司，也是标普 SmallCap 600的成员。2011年至2018年，Chin先生曾在大众仓储和亚历山大房地产担任财务领导职务，这两家公司均为上市公司，是标普 500指数的成员。2002年至2011年，Chin先生在全球公共会计师事务所EY担任执业注册会计师。Chin先生拥有加州大学洛杉矶分校的学士学位。Chin担任AI 2030的顾问委员会成员、AMBITION的委员会成员、美国心脏协会的筹款活动以及洛杉矶圣约之家的筹款活动并担任志愿者。他还积极为加州大学洛杉矶分校校友指导计划提供指导。Chin先生也是全国公司董事协会的成员和医疗保健财务管理协会的成员。
Eric Bing Chin has served as a Director of the Company since June 2025. Mr. Chin has served as the Principal Strategic Advisor and Chief Financial Officer of Xcelerant since 2022. Mr. Chin has served as a Board Advisor of PandoBlox and an Advisory Board Member of Owl Therapy since 2025.From 2023 to 2025, Mr. Chin served as a board member, Treasurer, and Secretary of Rhode Island Primary Care Physicians Corporation and as Chief Financial Officer of Akido. From 2018 to 2022, Mr. Chin served as Chief Financial Officer at Astrana Health, a publicly traded company and member of the S&P SmallCap 600. From 2011 to 2018, Mr. Chin served in finance leadership positions within Public Storage and Alexandria Real Estate Equities, both of which are publicly traded and members of the S&P 500. From 2002 to 2011, Mr. Chin served as a practicing CPA with EY, a global public accounting firm. Mr. Chin holds a B.A. degree from UCLA.Mr. Chin serves and volunteers as an advisory board member for AI 2030, a board member for AMBITION, a fundraiser for the American Heart Association, and a fundraiser for the Covenant House of Los Angeles. He also actively mentors for the UCLA Alumni mentoring program. Mr. Chin is also a member of the National Association of Corporate Directors and a member of the Healthcare Financial Management Association. - Eric Bing Chin自2025年6月起担任公司董事。Chin先生自2022年起担任XCelerant的首席战略顾问和首席财务官。Chin先生自2025年起担任PandoBlox的董事会顾问和Owl Therapy的顾问委员会成员。从2023年至2025年，Chin先生曾担任Rhode Island Primary Care Physicians Corporation的董事会成员、财务主管和秘书，并担任Akido的首席财务官。2018年至2022年，Chin先生在Astrana Health担任首席财务官，该公司是一家上市公司，也是标普 SmallCap 600的成员。2011年至2018年，Chin先生曾在大众仓储和亚历山大房地产担任财务领导职务，这两家公司均为上市公司，是标普 500指数的成员。2002年至2011年，Chin先生在全球公共会计师事务所EY担任执业注册会计师。Chin先生拥有加州大学洛杉矶分校的学士学位。Chin担任AI 2030的顾问委员会成员、AMBITION的委员会成员、美国心脏协会的筹款活动以及洛杉矶圣约之家的筹款活动并担任志愿者。他还积极为加州大学洛杉矶分校校友指导计划提供指导。Chin先生也是全国公司董事协会的成员和医疗保健财务管理协会的成员。
- Eric Bing Chin has served as a Director of the Company since June 2025. Mr. Chin has served as the Principal Strategic Advisor and Chief Financial Officer of Xcelerant since 2022. Mr. Chin has served as a Board Advisor of PandoBlox and an Advisory Board Member of Owl Therapy since 2025.From 2023 to 2025, Mr. Chin served as a board member, Treasurer, and Secretary of Rhode Island Primary Care Physicians Corporation and as Chief Financial Officer of Akido. From 2018 to 2022, Mr. Chin served as Chief Financial Officer at Astrana Health, a publicly traded company and member of the S&P SmallCap 600. From 2011 to 2018, Mr. Chin served in finance leadership positions within Public Storage and Alexandria Real Estate Equities, both of which are publicly traded and members of the S&P 500. From 2002 to 2011, Mr. Chin served as a practicing CPA with EY, a global public accounting firm. Mr. Chin holds a B.A. degree from UCLA.Mr. Chin serves and volunteers as an advisory board member for AI 2030, a board member for AMBITION, a fundraiser for the American Heart Association, and a fundraiser for the Covenant House of Los Angeles. He also actively mentors for the UCLA Alumni mentoring program. Mr. Chin is also a member of the National Association of Corporate Directors and a member of the Healthcare Financial Management Association.
- Gary M. Huff
-
Gary M. Huff自2025年10月起担任公司董事。自2019年以来，Huff先生一直担任Take Charge，LLC的总裁，这是一家由他创立的实验室商业咨询公司。在创立Take Charge，LLC之前，Huff先生曾在医疗保健和临床实验室行业担任多个高级行政领导职务，包括LabCorp Diagnostics的首席执行官、Baylor Genetics的首席执行官以及Solstas Lab Partners的首席运营官。Huff在领导复杂的医疗保健和实验室组织方面拥有丰富的经验，包括公开交易、私募股权支持和卫生系统拥有的业务。他的执行经验包括战略规划、运营领导、业务发展、并购、医疗合作伙伴关系和组织转型。他还带来了与《财富》500强公司合作的经验，并为医疗保健组织提供战略和运营方面的建议。Huff拥有印第安纳大学通识/心理学文学学士学位。
Gary M. Huff has served as a Director of the Company since October 2025. Since 2019, Mr. Huff has served as President of Take Charge, LLC, a laboratory business advisory firm that he founded. Prior to founding Take Charge, LLC, Mr. Huff held several senior executive leadership positions in the healthcare and clinical laboratory industries, including Chief Executive Officer of LabCorp Diagnostics, Chief Executive Officer of Baylor Genetics, and Chief Operating Officer of Solstas Lab Partners.Mr. Huff has extensive experience leading complex healthcare and laboratory organizations, including publicly traded, private equity backed, and health system owned businesses. His executive experience includes strategic planning, operational leadership, business development, mergers and acquisitions, healthcare partnerships, and organizational transformation. He also brings experience working with Fortune 500 companies and advising healthcare organizations on strategic and operational matters.Mr. Huff holds a Bachelor of Arts in General Studies/Psychology from Indiana University. - Gary M. Huff自2025年10月起担任公司董事。自2019年以来，Huff先生一直担任Take Charge，LLC的总裁，这是一家由他创立的实验室商业咨询公司。在创立Take Charge，LLC之前，Huff先生曾在医疗保健和临床实验室行业担任多个高级行政领导职务，包括LabCorp Diagnostics的首席执行官、Baylor Genetics的首席执行官以及Solstas Lab Partners的首席运营官。Huff在领导复杂的医疗保健和实验室组织方面拥有丰富的经验，包括公开交易、私募股权支持和卫生系统拥有的业务。他的执行经验包括战略规划、运营领导、业务发展、并购、医疗合作伙伴关系和组织转型。他还带来了与《财富》500强公司合作的经验，并为医疗保健组织提供战略和运营方面的建议。Huff拥有印第安纳大学通识/心理学文学学士学位。
- Gary M. Huff has served as a Director of the Company since October 2025. Since 2019, Mr. Huff has served as President of Take Charge, LLC, a laboratory business advisory firm that he founded. Prior to founding Take Charge, LLC, Mr. Huff held several senior executive leadership positions in the healthcare and clinical laboratory industries, including Chief Executive Officer of LabCorp Diagnostics, Chief Executive Officer of Baylor Genetics, and Chief Operating Officer of Solstas Lab Partners.Mr. Huff has extensive experience leading complex healthcare and laboratory organizations, including publicly traded, private equity backed, and health system owned businesses. His executive experience includes strategic planning, operational leadership, business development, mergers and acquisitions, healthcare partnerships, and organizational transformation. He also brings experience working with Fortune 500 companies and advising healthcare organizations on strategic and operational matters.Mr. Huff holds a Bachelor of Arts in General Studies/Psychology from Indiana University.
- Gregory Evan Feinberg
-
Gregory Evan Feinberg已被提名参加年会的董事会选举。2022年11月至2026年3月，Feinberg先生在Woodline Partners担任能源投资组合经理。2020年7月至2022年11月，担任一家专注于收购石油和天然气矿产权益的私人投资合伙企业的管理合伙人。从2008年8月至2020年7月，Feinberg先生在Citadel的全球股票平台担任能源和公用事业投资组合经理。在加入Citadel之前，他曾在瑞士信贷全球能源集团担任投资银行分析师。费恩伯格先生于2006年毕业于斯坦福大学。
Gregory Evan Feinberg has been nominated for election to the Board at the Annual Meeting. From November 2022 to March 2026, Mr. Feinberg served as an Energy Portfolio Manager at Woodline Partners. From July 2020 to November 2022, he served as a Managing Partner of a private investment partnership focused on acquiring oil and gas mineral interests. From August 2008 to July 2020, Mr. Feinberg served as an Energy and Utilities Portfolio Manager within Citadel's Global Equities platform. Prior to joining Citadel, he served as an Investment Banking Analyst in the Global Energy Group at Credit Suisse. Mr. Feinberg graduated from Stanford University in 2006. - Gregory Evan Feinberg已被提名参加年会的董事会选举。2022年11月至2026年3月，Feinberg先生在Woodline Partners担任能源投资组合经理。2020年7月至2022年11月，担任一家专注于收购石油和天然气矿产权益的私人投资合伙企业的管理合伙人。从2008年8月至2020年7月，Feinberg先生在Citadel的全球股票平台担任能源和公用事业投资组合经理。在加入Citadel之前，他曾在瑞士信贷全球能源集团担任投资银行分析师。费恩伯格先生于2006年毕业于斯坦福大学。
- Gregory Evan Feinberg has been nominated for election to the Board at the Annual Meeting. From November 2022 to March 2026, Mr. Feinberg served as an Energy Portfolio Manager at Woodline Partners. From July 2020 to November 2022, he served as a Managing Partner of a private investment partnership focused on acquiring oil and gas mineral interests. From August 2008 to July 2020, Mr. Feinberg served as an Energy and Utilities Portfolio Manager within Citadel's Global Equities platform. Prior to joining Citadel, he served as an Investment Banking Analyst in the Global Energy Group at Credit Suisse. Mr. Feinberg graduated from Stanford University in 2006.
高管简历
中英对照 | 中文 | 英文- Allen Barbieri
Allen Barbieri，2015年6月任职董事会以来，他一直担任Biomerica, Inc.董事会的成员。他目前担任Biosynthetic Technologies, LLC的董事长兼首席执行官（2009年12月以来）。此前，他曾任职Lancer Orthodontics, Inc.的董事会，并担任Lancer Orthodontics, Inc.的首席执行官（2004年4月至2008年6月）。1999年至2004年4月，他曾处于半退休状态，担任几个私人公司的董事会的董事。他一直担任Biomerica, Inc.的董事（1999年以来）。1998年至1999年，他曾担任BUY.COM（一个大型网络零售商，拥有超过2亿美元资金的风险投资）的总裁兼首席财务官。1994年至1998年，他曾担任Pacific National Bank（商业银行于1998年出售给US Bank）的总裁兼首席执行官。任职Pacific National Bank期间，他曾担任Alta Residential Mortgage Trust（按揭房地产投资信托基金，其最大股东和创始人是Lehman Brothers）的首席执行官。此前，他曾担任Capital Bancorp（商业银行控股公司）的总裁、First Federal Bank的首席财务官，以及Merrill Lynch Capital Markets（位于纽约）投资银行副合伙人。他持有Brigham Young University的工商管理学士学位，以及麻省理工学院的斯隆管理学院（the Massachusetts Institute of Technology, Sloan School of Management）的工商管理硕士学位。
Allen Barbieri has served as an Executive Vice Chairperson of the Board and Corporate Secretary of the Company since August 2020. Since January 2022, Mr. Barbieri has also concurrently served as the Chief Executive Officer of Küleon LLC, a small private biotech company engaged in development of therapeutic drugs targeting neurologic disorders. From October 1999 through August 2020, Mr. Allen Barbieri also served as an outside independent director of the Company. From March 2015 to April 2022, Mr. Allen Barbieri served as a member of the board of directors of CareTrust REIT, Inc. (NYSE:CTRE), a large publicly traded real estate investment trust, where he served as Chairman of the Corporate Governance and Nominating Committee and as a member of the Audit and Compensation Committees. From January 2010 to March 2018, Mr. Allen Barbieri served as the Chief Executive Officer of Biosynthetic Technologies, a privately held, renewable specialty chemicals company, with BP and Monsanto as primary owners. Prior to that, from April 2004 to September 2009, Mr. Barbieri served as the Chief Executive Officer of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico. From 1998 to 1999, he served as President and Chief Financial Officer of BUY.COM, a major internet retailer, and from 1994 to 1999 Mr. Barbieri was President and Chief Executive Officer of Pacific National Bank. Mr. Allen Barbieri holds an MBA from Massachusetts Institute of Technology (MIT).- Allen Barbieri，2015年6月任职董事会以来，他一直担任Biomerica, Inc.董事会的成员。他目前担任Biosynthetic Technologies, LLC的董事长兼首席执行官（2009年12月以来）。此前，他曾任职Lancer Orthodontics, Inc.的董事会，并担任Lancer Orthodontics, Inc.的首席执行官（2004年4月至2008年6月）。1999年至2004年4月，他曾处于半退休状态，担任几个私人公司的董事会的董事。他一直担任Biomerica, Inc.的董事（1999年以来）。1998年至1999年，他曾担任BUY.COM（一个大型网络零售商，拥有超过2亿美元资金的风险投资）的总裁兼首席财务官。1994年至1998年，他曾担任Pacific National Bank（商业银行于1998年出售给US Bank）的总裁兼首席执行官。任职Pacific National Bank期间，他曾担任Alta Residential Mortgage Trust（按揭房地产投资信托基金，其最大股东和创始人是Lehman Brothers）的首席执行官。此前，他曾担任Capital Bancorp（商业银行控股公司）的总裁、First Federal Bank的首席财务官，以及Merrill Lynch Capital Markets（位于纽约）投资银行副合伙人。他持有Brigham Young University的工商管理学士学位，以及麻省理工学院的斯隆管理学院（the Massachusetts Institute of Technology, Sloan School of Management）的工商管理硕士学位。
- Allen Barbieri has served as an Executive Vice Chairperson of the Board and Corporate Secretary of the Company since August 2020. Since January 2022, Mr. Barbieri has also concurrently served as the Chief Executive Officer of Küleon LLC, a small private biotech company engaged in development of therapeutic drugs targeting neurologic disorders. From October 1999 through August 2020, Mr. Allen Barbieri also served as an outside independent director of the Company. From March 2015 to April 2022, Mr. Allen Barbieri served as a member of the board of directors of CareTrust REIT, Inc. (NYSE:CTRE), a large publicly traded real estate investment trust, where he served as Chairman of the Corporate Governance and Nominating Committee and as a member of the Audit and Compensation Committees. From January 2010 to March 2018, Mr. Allen Barbieri served as the Chief Executive Officer of Biosynthetic Technologies, a privately held, renewable specialty chemicals company, with BP and Monsanto as primary owners. Prior to that, from April 2004 to September 2009, Mr. Barbieri served as the Chief Executive Officer of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico. From 1998 to 1999, he served as President and Chief Financial Officer of BUY.COM, a major internet retailer, and from 1994 to 1999 Mr. Barbieri was President and Chief Executive Officer of Pacific National Bank. Mr. Allen Barbieri holds an MBA from Massachusetts Institute of Technology (MIT).
- Zackary Irani
Zackary Irani，他担任公司的董事。1997年4月29日以来，他担任公司的董事长和首席执行官。此前，他担任公司的业务发展副总裁。1986年以来，他一直担任公司的职务。在2008年和2009年的财政期间，他也担任Lancer Orthodontics, Inc.的董事长。从1997年4月到2004年4月，他担任Lancer的首席执行官。
Zackary Irani has served as a director and Chief Executive Officer of the Company since April 1997. Mr. Irani served as Chairperson of the Board from April 1997 until June 2024. Prior to that time, Mr. Zackary Irani served as the Company's Vice President of Business Development. He has been an employee of the Company since 1986. During the fiscal years 2008 and 2009, Mr. Irani also served as Chairperson of the Board of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico, and served as Lancer's Chief Executive Officer from April 1997 until April 2004. Mr. Irani holds a B.S. degree and an MBA degree from the Paul Merage School of Business at the University of California, Irvine.- Zackary Irani，他担任公司的董事。1997年4月29日以来，他担任公司的董事长和首席执行官。此前，他担任公司的业务发展副总裁。1986年以来，他一直担任公司的职务。在2008年和2009年的财政期间，他也担任Lancer Orthodontics, Inc.的董事长。从1997年4月到2004年4月，他担任Lancer的首席执行官。
- Zackary Irani has served as a director and Chief Executive Officer of the Company since April 1997. Mr. Irani served as Chairperson of the Board from April 1997 until June 2024. Prior to that time, Mr. Zackary Irani served as the Company's Vice President of Business Development. He has been an employee of the Company since 1986. During the fiscal years 2008 and 2009, Mr. Irani also served as Chairperson of the Board of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico, and served as Lancer's Chief Executive Officer from April 1997 until April 2004. Mr. Irani holds a B.S. degree and an MBA degree from the Paul Merage School of Business at the University of California, Irvine.
- Xiaoxuan Qu
曲晓轩自2026年8月起担任公司首席财务官、首席会计官，自2026年1月起担任财务副总裁。她于2023年6月加入公司，此前于2024年1月开始担任公司财务总监。在加入公司之前，曲女士于2021年8月至2023年5月在公共会计师事务所HCVT担任审计和鉴证职务，此前曾在安永会计师事务所担任税务职务。曲女士拥有加州大学欧文分校Paul Merage商学院硕士学位和圣托马斯大学会计学学士学位。
Xiaoxuan Qu has served as the Company's Principal Financial Officer and Principal Accounting Officer since August 2026, and as Vice President of Finance since January 2026. She joined the Company in June 2023 and previously served as Corporate Controller beginning in January 2024.Prior to joining the Company, Ms. Qu served in audit and assurance roles at HCVT, a public accounting firm, from August 2021 to May 2023, and previously held tax positions at Ernst & Young LLP. Ms. Qu holds a master's degree from the Paul Merage School of Business at the University of California, Irvine, and a bachelor's degree in accounting from St. Thomas University.- 曲晓轩自2026年8月起担任公司首席财务官、首席会计官，自2026年1月起担任财务副总裁。她于2023年6月加入公司，此前于2024年1月开始担任公司财务总监。在加入公司之前，曲女士于2021年8月至2023年5月在公共会计师事务所HCVT担任审计和鉴证职务，此前曾在安永会计师事务所担任税务职务。曲女士拥有加州大学欧文分校Paul Merage商学院硕士学位和圣托马斯大学会计学学士学位。
- Xiaoxuan Qu has served as the Company's Principal Financial Officer and Principal Accounting Officer since August 2026, and as Vice President of Finance since January 2026. She joined the Company in June 2023 and previously served as Corporate Controller beginning in January 2024.Prior to joining the Company, Ms. Qu served in audit and assurance roles at HCVT, a public accounting firm, from August 2021 to May 2023, and previously held tax positions at Ernst & Young LLP. Ms. Qu holds a master's degree from the Paul Merage School of Business at the University of California, Irvine, and a bachelor's degree in accounting from St. Thomas University.